2025-05-19-Jefferies-礼来（LLY）_幻灯片礼来公司临床前阿尔茨海默病深度探讨-今日（5月19日）美国东部时间下午1200_78页_13mb

Eli Lilly (LLY) Alzheimer's Drug Donanemab-ALZ3 Analysis

1. Investment Thesis

• Jefferies assigns BUY rating with $1,057 price target (+40% upside).
• Focus on preclinical Alzheimer's (early AD) market, estimated $10-15B+ opportunity for Donanemab.
• Key drivers: Use of blood-based pTau-217 test for early diagnosis, potential to expand addressable market significantly vs. current late-stage AD treatments.

2. Donanemab-ALZ3 (TB-3) Clinical Trial

• Trial Design: Phase 3 trial targeting preclinical AD patients with blood pTau-217 positivity. Primary endpoint is time to clinical progression measured by CDR-GS score.
• Potential Efficacy:
  • Base case: HR ~0.5-0.6 (40-50% slowing of progression), OR 0.3-0.4 for best-case scenario.
  • CDR-SB analysis suggests ~40-60% slowing in progression, aligning with base case efficacy estimates.
• Timing: Possible readout as early as Q4 2025/1H 2026, due to potentially lower event rates in TB-3 population (66 CL baseline vs. 102 CL in TB-2) and possible trial powering optimization.

3. Safety Data

• ARIA Rates: Blinded ARIA-E rate in TB-3 reported at 6.7%, compared to ~2% in placebo, suggesting potential pbo-adj. 11% ARIA-E in Donanemab arm.
• Redosing Trend: Potential ARIA reduction with modified titration regimen, leading to ~6.5% ARIA-E and ~11% ARIA-H in the new cohort.
• Payer Appeal: Shorter 9-month dosing vs. continuous regimens like lecanemab, potentially reducing overall cost.

4. Market Potential

• Preclinical AD Market: Estimated ~20Mn patients in the U.S. by 2030, representing a $10-15B peak revenue opportunity for Donanemab.
• Pricing & Adoption: Payer-friendly dosing schedule and potential for early diagnosis via pTau-217 test could drive market penetration.
• Competition: Remternetug (subQ formulation) being developed as a follow-on therapy, potentially expanding LLY’s AD portfolio.

5. Market-Scale Implications

• Revenue Projections: Illustrative scenario shows peak sales of $11.2B-$28.0B at 20-50% diagnosis rates.
• Patient Acceptance: High willingness among Americans (91%) to undergo preclinical screening if effective treatments are available.

6. Key Questions/Risks

• Clarity on patient segmentation criteria for pTau-217 testing (e.g., age, family history).
• Payer restrictions on early diagnosis/treatment initiation could limit market access.
• Execution risk in redosing strategy and data readouts.

7. Analyst Certifications

• Akash Tewari et al.: certify projections and views reflect "personal views" and independence, with no compensation tied directly to recommendations.
• Disclosures on potential conflicts of interest, particularly Jefferies’ business relationships with studied companies.

8. Rating History

• Reiterated BUY rating; unchanged PT of $1,057 (up 40% from current price).

Conclusion

Donanemab-ALZ3 represents a transformative potential in Alzheimer's therapy, targeting a significantly expanded patient population with blood-based early detection. Success could shift treatment paradigms, but outcomes depend on efficacy, safety, and payer adoption. LLY's investment in oral GLP-1 (Orforglipron) and Alzheimer’s provides a diversified platform, supported by strong analyst confidence.